Logo

Asuragen, Biogen Idec Sign Rx/Dx Co-development Pact

Jul 20, 2009

NEW YORK (GenomeWeb News) – Asuragen said today that it will work with Biogen Idec to develop a companion diagnostic test for a cancer drug.

Asuragen will use its RNA technologies to develop an assay that could help select which patients will benefit from a drug candidate that Biogen Idec now has in clinical development.

The Austin, Texas-based Asuragen currently offers its Signature Genetic Testing and Oncology Testing product lines, as well as its Armored RNA technology.

Filed under

Diagnostics
Companion Diagnostics
Cancer
Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.